Search

Objective: Pulmonary embolism is a life-threatening condition often resulting from deep vein thrombosis, with significant morbidity and mortality. Thrombolytic therapy is a common treatment, particularly in high-risk cases. Despite numerous studies on pulmonary embolism, a comprehensive bibliometric analysis of research trends and impacts, especially regarding thrombolytic therapy, is lacking. Materials and Methods: This bibliometric analysis utilized the Web of Science database to collect and evaluate literature published between January 1, 2004, and December 31, 2023. A total of 282 articles were selected based on specific inclusion criteria. Data were analyzed using VOSviewer and Bibliometrix R, focusing on publication trends, citation counts, and collaborative networks. Results: The analysis identified a progressive increase in pulmonary embolism-related publications, peaking in 2020 and 2022. The United States led in publication volume, followed by Turkey and China. Despite high publication numbers, Turkey's citation count was relatively low, highlighting potential gaps in research impact and quality. The study also revealed that European countries exhibit stronger international collaborations compared to the United States. Key research trends shifted post-2018 towards topics such as mortality, bleeding, COVID-19, and extracorporeal membrane oxygenation. Conclusion: This bibliometric analysis provides a detailed overview of the research landscape on pulmonary embolism and thrombolytic therapy, highlighting evolving research priorities, the significance of funding opportunities, and the importance of international collaborations. The study's insights can guide future research directions and inform clinical practices, ultimately aiming to improve patient outcomes. [ABSTRACT FROM AUTHOR]

Objective: Acute ischemic stroke (AIS) patients with congestive heart failure (HF) that present with various risk factors are less likely to receive recombinant tissue plasminogen activator (rtPA). The risk factors associated with excluding AIS patients with congestive heart failure (AIS-HF) from rtPA therapy have not been fully established. Methods: Retrospective data for 5469 AIS patients comprised of 590 AIS patients with HF and 4879 AIS patients without HF were collected from a regional stroke registry between January 2010 and June 2016. Baseline risk factors were analyzed using logistic regression analysis to determine the risk factors associated with rtPA exclusion in AIS-HF patients. Results: In the adjusted analysis, AIS-HF patients that that did not receive rtPA were more likely to be older (OR = 0.982, 95% CI, 0.966-1, P =.020), presented with coronary artery disease (OR = 0.618, 95% CI, 0.391-0.98, P =.040), and with an elevated INR (OR = 0.326, 95% CI, 0.129-0.82, P =.018). AIS-HF patients that were included for rtPA therapy were more likely to show improvement in ambulatory status (OR = 1.69, 95% CI, 1.058-2.7, P =.028). The discriminating power of the model was strong with an area under the curve (AUROC) = 0.668 (95% CI, 0.611-0.724, P <.001). Conclusion: Our study establishes the associations between stroke risk factors and exclusion from rtPA therapy. This finding suggests the need to develop management strategies for older HF patients with carotid artery disease and an elevated INR to improve their eligibility for rtPA treatment following an acute ischemic stroke. [ABSTRACT FROM AUTHOR]